We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK...
Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders PR Newswire NEW YORK, Jan. 18, 2017 NEW YORK, Jan. 18, 2017 /PRNewswire/ -- WeissLaw LLP is...
Harwood Feffer LLP Announces Investigation of ARIAD Pharmaceuticals, Inc. PR Newswire NEW YORK, Jan. 9, 2017 NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is...
Rigrodsky & Long, P.A.: Do you own shares of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA)? Did you purchase any of your shares prior to January 9, 2017? Do you think the...
ARIAD Stockholders to Receive $24.00 per Share in Cash ARIAD Pharmaceuticals (NASDAQ:ARIA) (“ARIAD”) today announced it has entered into a definitive agreement to be acquired by Takeda...
– Significantly Enhances Takeda’s Global Oncology Portfolio – – Accretive to FY2018 Underlying Core Earnings – – Reinforces Takeda’s Commitment to Developing Medicines for Patients...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.P. Morgan Healthcare...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. The company has...
- Analysis Also Demonstrated Intracranial Median Progression-Free Survival (PFS) of 18.4 Months - 55 Percent Confirmed Systemic Objective Response Rate - Investor and Analyst Webcast...
~Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent~Pooled Phase 1 and PACE analysis of CP-CML...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions